人非小细胞肺癌NCI—H1975细胞的异质性研究  

Research on heterogeneity of human non-small cell lung cancer cell line NCI-H1975

作　　者：罗凯[1] 王倩[1] 仇秦威[1] 彭聪[1] 邓应根 黎谢梦丹 贾小婷[1] 张志杰[1] 郑国培[1] 谷依学[1] 贺智敏[1] 

机构地区：[1]广州医科大学附属肿瘤医院、肿瘤研究所,广州510095

出　　处：《中国医师杂志》2016年第10期1484-1487,共4页Journal of Chinese Physician

基　　金：广州市卫计委医药卫生科技项目（20161A011086）;广东省中医药局科研项目（20161179）

摘　　要：目的探讨人非小细胞肺癌NCI-H1975细胞的异质性及其与药物反应性的关系。方法利用有限稀释法获得NCI-H1975细胞单克隆化子细胞，并对母细胞和部分单克隆化子细胞行表型、药物反应性和表皮生长因子受体（EGFR）基因突变检测，分析NCI-H1975细胞的克隆异质性特征及其与药物反应性的关系。结果获得13个单克隆化的NCI-H1975子细胞，与母细胞相比，各子细胞在细胞增殖能力、吉非替尼敏感性和顺铂敏感性方面差异有统计学意义（P〈0．05），在EGFR基因突变状态方面未见差异。结论NCI-H1975细胞存在细胞增殖能力等表型指标和药物反应性指标的异质性，并与药物治疗的反应性和耐药相关。Objective To investigate the heterogeneity of human non-small cell lung cancer cell line NCI-H1975 and its relationship with drug reactivity. Methods Monoclonal subpopulations of NCI- H1975 were isolated by limiting dilution and its phenotype, drug reactivity and epidermal growth factor re- ceptor （EGFR） gene mutation were identified. The heterogeneity of NCI-H1975 and its relationship with drug reactivity were analyzed. Results Thirteen monoclonal subpopulations of NCI-H1975 were isolated and its proliferation ability and sensitivity to gefitinib and cisplatin had significant differences compared to NCI-H1975 （ P 〈 0. 05 ）. There were no difference in EGFR gene mutation between NCI-H1975 and its subpoputations. Conclusions NCI-H1975 were heterogeneous on proliferation ability and drug reactivity and its heterogeneity were associated with sensitivity and resistance of drug treatment.

关 键 词：癌  非小细胞肺 遗传异质性 生物学标记 药理学 

分 类 号：R734.2[医药卫生—肿瘤]